Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197

Area of Science:

• Pharmacology
• Immunology
• Drug Development

Background:

• The p38 mitogen-activated protein kinase (p38) pathway is crucial for inflammatory cytokine regulation.
• Clinical trials with p38 inhibitors have shown limited efficacy for chronic inflammation.

Purpose of the Study:

• To characterize the population pharmacokinetics (PK) of BCT197 in healthy volunteers.
• To investigate the relationship between BCT197 exposure and its pharmacodynamic (PD) effect on lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFα) production.

Main Methods:

• Population PK modeling using a two-compartment model with mixed-order absorption and limited-capacity tissue binding.
• Ex vivo assessment of TNFα inhibition as a measure of p38 pathway activity.

Main Results:

• PK analysis revealed complex absorption and tissue binding characteristics for BCT197.
• A PK-PD relationship showed that TNFα suppression decreased over time despite continuous drug exposure, suggesting tolerance development.
• Simulations indicated that intermittent dosing might be more effective than continuous dosing.

Conclusions:

• The inflammatory response may develop mechanisms to bypass p38 activity over time.
• Intermittent dosing strategies for BCT197 could potentially enhance clinical benefit in treating chronic inflammatory conditions by mitigating tolerance.